Attention Deficit Hyperactivity Disorder (ADHD) - Drug Pipeline Landscape, 2023
Description
Attention Deficit Hyperactivity Disorder (ADHD) is a mental health condition that can cause unusual levels of hyperactivity and impulsive behaviours. People with ADHD may also have trouble focusing their attention on a single task or sitting still for long periods of time.
Attention deficit hyperactivity disorder caused by reduction in dopamine which is a chemical in the brain that helps move signals from one nerve to another and plays a role in triggering emotional responses and movements.
Signs and symptoms of Attention deficit hyperactivity disorder includes having trouble focusing or concentrating on tasks, being forgetful about completing tasks, being easily distracted, having difficulty sitting still, interrupting people while they’re talking and talk excessively.
Doctors most often diagnose attention deficit hyperactivity disorder based on the presence of persistent symptoms that have occurred over a period and are noticeable over the past six months.
The most common investigative treatments include behavioral therapies, medication, and psychotherapy. Central nervous system (CNS) stimulants are the most prescribed ADHD medications. Symptoms can be eased through lifestyle changes and home remedies like eating a nutritious, balanced diet.
Report Highlights
Global Insight Service’s, Attention Deficit Hyperactivity Disorder (ADHD) - Drug Pipeline Landscape, 2023 report provides an overview of the Attention Deficit Hyperactivity Disorder (ADHD) pipeline drugs. This report covers detailed insights on Attention Deficit Hyperactivity Disorder (ADHD) drugs under development, assessment by target, mechanism of action, route of administration and molecule type.Product pipeline by companies, stage of development and key regulatory designations, deals and milestones have been presented to provide insights and thus help industry participants in their decision making. Attention Deficit Hyperactivity Disorder (ADHD) pipeline report helps gain insights on drugs which are under development stage of drug development process across globally.
Methodology
The research process includes extensive secondary research on public domain and other authentic sources to add or update the pipeline products information. The secondary research sources include, but are not limited to company websites, annual reports, financial reports, company pipeline chart, investor presentations and SEC filings, journals and conferences, and clinical trials registries.
Scope
The pipeline landscape report provides analysis of pipeline products based on several stages of development ranging from Discovery to Pre-Registration. The report provides a review of pipeline therapeutics by companies based on information derived from company and industry-specific sources. The pipeline report covers assessment of therapeutics by mechanism of action (MoA), drug target, route of administration (RoA) and molecule type. Comprehensive profiles of the pipeline products with details such as company overview, development stage; molecule type, target, mechanism of action, route of administration, dosage form, regulatory designations, key deals, clincial trials, and key upcoming milestones are included.
Reasons to Buy
Helps to find and recognize significant therapeutics under development. Thorough understanding of pipeline structure and helps in developing corrective measures for pipeline projects.
Effective R&D strategies can be developed with deep knowledge of competitor information, analysis, and insights.
Plan collaborations with various industry partners that have role in some or the other stage of drug development such as contract manufacturing, co-development, contract research organization and commercialization etc.
Helps to create in-licensing and out-licensing opportunities by identifying prospective partners with attractive projects to expand business potential and scope.
Please Note: This report will be delivered by publisher within 3-4 business days of order confirmation.
Attention deficit hyperactivity disorder caused by reduction in dopamine which is a chemical in the brain that helps move signals from one nerve to another and plays a role in triggering emotional responses and movements.
Signs and symptoms of Attention deficit hyperactivity disorder includes having trouble focusing or concentrating on tasks, being forgetful about completing tasks, being easily distracted, having difficulty sitting still, interrupting people while they’re talking and talk excessively.
Doctors most often diagnose attention deficit hyperactivity disorder based on the presence of persistent symptoms that have occurred over a period and are noticeable over the past six months.
The most common investigative treatments include behavioral therapies, medication, and psychotherapy. Central nervous system (CNS) stimulants are the most prescribed ADHD medications. Symptoms can be eased through lifestyle changes and home remedies like eating a nutritious, balanced diet.
Report Highlights
Global Insight Service’s, Attention Deficit Hyperactivity Disorder (ADHD) - Drug Pipeline Landscape, 2023 report provides an overview of the Attention Deficit Hyperactivity Disorder (ADHD) pipeline drugs. This report covers detailed insights on Attention Deficit Hyperactivity Disorder (ADHD) drugs under development, assessment by target, mechanism of action, route of administration and molecule type.Product pipeline by companies, stage of development and key regulatory designations, deals and milestones have been presented to provide insights and thus help industry participants in their decision making. Attention Deficit Hyperactivity Disorder (ADHD) pipeline report helps gain insights on drugs which are under development stage of drug development process across globally.
Methodology
The research process includes extensive secondary research on public domain and other authentic sources to add or update the pipeline products information. The secondary research sources include, but are not limited to company websites, annual reports, financial reports, company pipeline chart, investor presentations and SEC filings, journals and conferences, and clinical trials registries.
Scope
The pipeline landscape report provides analysis of pipeline products based on several stages of development ranging from Discovery to Pre-Registration. The report provides a review of pipeline therapeutics by companies based on information derived from company and industry-specific sources. The pipeline report covers assessment of therapeutics by mechanism of action (MoA), drug target, route of administration (RoA) and molecule type. Comprehensive profiles of the pipeline products with details such as company overview, development stage; molecule type, target, mechanism of action, route of administration, dosage form, regulatory designations, key deals, clincial trials, and key upcoming milestones are included.
Reasons to Buy
Helps to find and recognize significant therapeutics under development. Thorough understanding of pipeline structure and helps in developing corrective measures for pipeline projects.
Effective R&D strategies can be developed with deep knowledge of competitor information, analysis, and insights.
Plan collaborations with various industry partners that have role in some or the other stage of drug development such as contract manufacturing, co-development, contract research organization and commercialization etc.
Helps to create in-licensing and out-licensing opportunities by identifying prospective partners with attractive projects to expand business potential and scope.
Please Note: This report will be delivered by publisher within 3-4 business days of order confirmation.
Table of Contents
95 Pages
- List of Tables
- List of Figures
- 1. Introduction
- 1.1 Attention Deficit Hyperactivity Disorder (ADHD) – Pipeline Drugs, 2023 - Coverage
- 2. Disease Overview – Attention Deficit Hyperactivity Disorder (ADHD)
- 2.1 Causes
- 2.2 Signs and Symptoms
- 2.3 Diagnosis
- 2.4 Disease Management
- 3. Attention Deficit Hyperactivity Disorder (ADHD) – Pipeline Drugs Development - Overview
- 3.1 Comparative Analysis by Stage of Development
- 3.2 Number of Products under Development by Companies, 2023
- 3.3 Products under Development by Companies, 2023
- 4. Assessment of Therapeutics
- 4.1 Assessment by Target
- 4.2 Assessment by Mechanism of Action
- 4.3 Assessment by Molecule Type
- 4.3 Assessment by Route of Administration
- 5. Drug Profiles
- 5.1 Late-Stage Drugs - Pre-Registration
- 5.1.1 TRN-110
- 5.2 Clinical Stage Drugs - Phase III
- 5.2.1 Centanafadine
- 5.2.2 CTx-1301
- 5.2.3 Prospecta
- 5.3 Clinical Stage Drugs - Phase II
- 5.3.1 Mazindol
- 5.3.2 MM-120
- 5.3.3 PDC-1421
- 5.4 Clinical Stage Drugs - Phase I
- 5.4.1 ADAIR
- 5.4.2 AGX-201
- 5.4.3 Brilaroxazine
- 5.4.4 SKL-13865
- 5.4.5 TAH9901
- 5.4.6 TAH9922
- 5.5 Early-Stage Drugs - IND/CTA Filed
- 5.5.1 Atomoxetine Hydrochloride (Oral Liquid Formulation)
- 5.6 Early-Stage Drugs - Preclinical
- 5.6.1 3Z-20-001
- 5.6.2 3Z-20-002
- 5.6.3 3Z-20-003
- 5.6.4 3Z-20-004
- 5.6.5 ADMIR
- 5.6.6 CTx-1302
- 5.6.7 INV-400
- 5.6.8 NNI-351
- 5.6.9 PF8001
- 5.6.10 PF8026
- 5.6.11 SPN-443
- 5.6.12 TRN-148
- 5.7 Early-Stage Drugs - Discovery
- 5.7.1 PCT-3012
- 6. Key Regulatory Designations
- 7. Key Deals
- 8. Key Upcoming Milestones
- 9. Key Companies Involved
- 9.1 3Z ehf
- 9.2 AgoneX Biopharmaceuticals Inc
- 9.3 BioLite, Inc
- 9.4 Cingulate Therapeutics
- 9.5 Ensysce Biosciences Inc
- 9.6 INVENT Pharmaceuticals Inc
- 9.7 Materia Medica Holding
- 9.8 Mind Medicine, Inc.
- 9.9 NeuroNascent Inc
- 9.10 NLS Pharmaceutics
- 9.11 Otsuka Pharmaceutical Co Ltd
- 9.12 OWP Pharmaceuticals Inc
- 9.13 PolyCore Therapeutics LLC
- 9.14 Reviva Pharmaceuticals Inc
- 9.15 SK Biopharmaceuticals Co Ltd
- 9.16 Supernus Pharmaceuticals Inc
- 9.17 Taho Pharmaceuticals Ltd
- 9.18 Tris Pharma Inc
- 9.19 Vallon Pharmaceuticals Inc
- 10. Dormant Drugs
- 10.1 Inactive Drugs
- 10.2 Discontinued Drugs
- 11. Appendix
- List of Tables
- Table 1.1 Number of Products Under development for Attention Deficit Hyperactivity Disorder (ADHD)
- Table 1.2 Number of Products under Development by Companies
- Table 1.3 Products under Development by Companies
- Table 1.4 Products by Targets
- Table 1.5 Products by Mechanism of Action
- Table 1.6 Products by Molecule Type
- Table 1.7 Products by Route of Administration
- Table 2.1 Clinical Trial Details - Centanafadine/Otsuka Pharmaceutical Co Ltd
- Table 2.2 Clinical Trial Details - CTx-1301/Cingulate Therapeutics
- Table 2.3 Clinical Trial Details - Prospecta/Materia Medica Holding
- Table 2.5 Clinical Trial Details - Mazindol/NLS Pharmaceutics
- Table 2.6 Clinical Trial Details - MM-120/Mind Medicine, Inc.
- Table 2.7 Clinical Trial Details - PDC-1421/BioLite, Inc
- Table 2.8 Clinical Trial Details - ADAIR/Vallon Pharmaceuticals Inc
- Table 3.1 Regulatory Designations
- Table 4.1 Inactive Drugs
- List of Figures
- Figure 1.1 Number of Products under Development for Attention Deficit Hyperactivity Disorder (ADHD), 2023
- Figure 1.2 Products by Top 5 Targets and Stage of Development for Attention Deficit Hyperactivity Disorder (ADHD), 2023
- Figure 1.3 Products by Top 5 Mechanism of Action and Stage of Development for Attention Deficit Hyperactivity Disorder (ADHD), 2023
- Figure 1.4 Products by Top 5 Molecule Type and Stage of Development for Attention Deficit Hyperactivity Disorder (ADHD), 2023
- Figure 1.5 Products by Top 5 Route of Administration and Stage of Development for Attention Deficit Hyperactivity Disorder (ADHD), 2023
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
